203 related articles for article (PubMed ID: 33955821)
1. Healthcare resource use and indirect costs associated with migraine in Italy: results from the
Martelletti P; Schwedt TJ; Vo P; Ritrovato D; Reilly MC; Naclerio M; Ranjan P; Kleebach J; Joshi P
J Med Econ; 2021; 24(1):717-726. PubMed ID: 33955821
[TBL] [Abstract][Full Text] [Related]
2. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland.
Sumelahti ML; Sumanen M; Sumanen MS; Tuominen S; Vikkula J; Honkala SM; Rosqvist S; Korolainen MA
J Headache Pain; 2020 Sep; 21(1):118. PubMed ID: 32993489
[TBL] [Abstract][Full Text] [Related]
3. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
[TBL] [Abstract][Full Text] [Related]
4. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
[TBL] [Abstract][Full Text] [Related]
5. Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom.
Vo P; Fang J; Bilitou A; Laflamme AK; Gupta S
J Headache Pain; 2018 Sep; 19(1):82. PubMed ID: 30203163
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of migraine in Latvia and Lithuania: direct and indirect costs.
Lublóy Á
BMC Public Health; 2019 Sep; 19(1):1242. PubMed ID: 31500616
[TBL] [Abstract][Full Text] [Related]
7. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
[TBL] [Abstract][Full Text] [Related]
8. Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
Dodick DW; Reed ML; Lee L; Balkaran BL; Umashankar K; Parikh M; Gandhi P; Buse DC
Headache; 2024 Apr; 64(4):361-373. PubMed ID: 38523435
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention.
Cowan R; Stark-Inbar A; Rabany L; Harris D; Vizel M; Ironi A; Vieira JR; Galen M; Treppendahl C
J Med Econ; 2023; 26(1):656-664. PubMed ID: 37083448
[TBL] [Abstract][Full Text] [Related]
10. Burden of migraine in Brazil: A cross-sectional real-world study.
Souza MNP; Cohen JM; Piha T; Ribalov R; Lengil T; van der Laan A; Calderaro M; Lee LK
Headache; 2022 Nov; 62(10):1302-1311. PubMed ID: 36426738
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
12. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain.
Vo P; Swallow E; Wu E; Zichlin ML; Katcher N; Maier-Peuschel M; Naclerio M; Ritrovato D; Tiwari S; Joshi P; Ferraris M
J Med Econ; 2021; 24(1):900-907. PubMed ID: 34311659
[TBL] [Abstract][Full Text] [Related]
13. Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment.
Buse DC; Pozo-Rosich P; Dupont-Benjamin L; Balkaran BL; Lee L; Jauregui A; Gandhi P; Parikh M; Reuter U
J Headache Pain; 2023 Aug; 24(1):115. PubMed ID: 37612633
[TBL] [Abstract][Full Text] [Related]
14. Annual indirect costs secondary to headache disability in Brazil.
Oliveira AB; Queiroz LP; Sampaio Rocha-Filho P; Sarmento EM; Peres MF
Cephalalgia; 2020 May; 40(6):597-605. PubMed ID: 31757169
[TBL] [Abstract][Full Text] [Related]
15. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey.
Kikui S; Chen Y; Todaka H; Asao K; Adachi K; Takeshima T
J Headache Pain; 2020 Sep; 21(1):110. PubMed ID: 32912187
[TBL] [Abstract][Full Text] [Related]
16. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.
Chandran A; Schaefer C; Ryan K; Baik R; McNett M; Zlateva G
J Manag Care Pharm; 2012; 18(6):415-26. PubMed ID: 22839682
[TBL] [Abstract][Full Text] [Related]
17. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia.
Wong LP; Alias H; Bhoo-Pathy N; Chung I; Chong YC; Kalra S; Shah ZUBS
J Headache Pain; 2020 Jun; 21(1):68. PubMed ID: 32513174
[TBL] [Abstract][Full Text] [Related]
18. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace.
Shimizu T; Sakai F; Miyake H; Sone T; Sato M; Tanabe S; Azuma Y; Dodick DW
J Headache Pain; 2021 Apr; 22(1):29. PubMed ID: 33882816
[TBL] [Abstract][Full Text] [Related]
19. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
20. Burden of migraine in the United States: disability and economic costs.
Hu XH; Markson LE; Lipton RB; Stewart WF; Berger ML
Arch Intern Med; 1999 Apr; 159(8):813-8. PubMed ID: 10219926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
